Preventive Program in Multiple Sclerosis
27 gennaio 2021 aggiornato da: Kamila Řasová
Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
This study monitor the immediate and persistent impact of a preventive complex six-month program specifically developed for newly diagnosed people with multiple sclerosis on fatigue, mental and physical fitness, and quality of life.
The study determined whether changes in clinical function are related to changes in neurohormones, and whether the effect of therapy is dependent on the active approach of study participants.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The patients who were newly diagnosed with MS underwent a six-month preventive comprehensive program, which included individual physiotherapy focused on the treatment of functional disorders of the loco-motor system and therapy on a neurophysiological basis, group psychotherapy and controlled aerobic training.
The participants were examined three times - before the start of the physiotherapy program, immediately after its completion and six months apart.
Influence on physical fitness (spiroergometric examination), fatigue (Modify Fatigue Impact Scale, fatigue scale for motor and cognitive functions), depression (Beck scale for evaluation of depression), admission of disease RS (Inventory of admission of multiple sclerosis, quality of life) life and selected neurohormones (dehydroepiandrosterone-DHEA, dehydroepiandrosterone sulphate - DHEAS, cortisol).
Tipo di studio
Interventistico
Iscrizione (Effettivo)
17
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Praha, Cechia, 128 00
- Kamila Řasová
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 70 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- definite MS
- stable clinical status in the preceding 3 months
- imumnomodulatory treatment for at least two years (including glatiramer acetate, interferon beta-1a, 1b, mitoxantrone, fingolimod, natalizumab)
- Expanded Disability Status Scale (EDSS)≤6
- predominant motor impartment
- six months or more without any physiotherapy
- ability to undergo ambulatory physiotherapy
Exclusion Criteria:
- other neurological disease or conditions disabling movement
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis
Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
|
Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes.
Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Questionnaires - The Fatigue scale for motor and cognitive functions
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
FSMC - is an assessment of MS-related cognitive and motor fatigue.
A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question.
Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue).
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - The Satisfaction With Life Scale
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
The scale measures the current level of satisfaction with one's own life.
Investigators express the extent to which they agree or disagree with the five statements.
The rating scale contains 7 points (1- "strongly disagree" and 7 - "strongly agree").
The maximum number of points on the scale is 35 (maximum satisfaction with your life) and the minimum number of points is 5 (dissatisfaction with your life).
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - Multiple Sclerosis Acceptance Questionnaire
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
This questionnaire consists of 20 statements that relate to the lives of patients with MS.
The rating scale has seven points (1- "never pays" to 7 - "always pays").
The minimum value is 20 (minimum adaptation to the diagnosis of MS for a large limitation of the normal life of MS) and the maximum value is 140 points (maximum adaptation to the diagnosis of MS - without the limitation of the normal life of MS) .
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Questionnaires - Beck Depression Inventory Score
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
questionnaire is divided into thirteen categories and patients select a statement in each category which best fits their current feelings on the scale ranged from 0 (the best feelings) to 3 (the worst feelings).
The maximum value of the total scale is 39 and shows the worst feeling of the person.
|
change after six months of the program and after next six moths without therapy is being assessed
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ventilation capacity
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
Forced vital capacity = FVC [ l ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Metabolic utilization
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
maximal muscle performance = Rmax [ Watt kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Maximal oxygen uptake
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
VO2 kg-1 [ VO2max.kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Maximal oxygen pulse
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
VO2 HR-1 kg-1 [ VO2max.TF-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Relative ventilation
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
[ VEmax.kg-1 ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Cortisol
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of cortisol [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Cortizone
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of cortisone[ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
Dehydroepiandrosterone (DHEA)
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
7β-hydroxydehydroepiandrosterone (7β-OH-DHEA )
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of 7β-OH-DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
|
7-oxo dehydroepiandrosterone (7-oxo-DHEA )
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
levels of 7-oxo-DHEA [ ng/mL ]
|
change after six months of the program and after next six moths without therapy is being assessed
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Questionnaires - Modified Fatigue Impact Scale
Lasso di tempo: change after six months of the program and after next six moths without therapy is being assessed
|
This scale consists of 21 statements that describe how often fatigue has affected a person during last four weeks.
Each statement is ranged from 0 (never) to 4 (almost, always).
The maximum value of the scale is 84.
|
change after six months of the program and after next six moths without therapy is being assessed
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Kamila Řasová, Ph.D., Third Faculty of Medicine Charles University
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 ottobre 2017
Completamento primario (Effettivo)
1 ottobre 2019
Completamento dello studio (Effettivo)
1 ottobre 2019
Date di iscrizione allo studio
Primo inviato
20 novembre 2020
Primo inviato che soddisfa i criteri di controllo qualità
9 dicembre 2020
Primo Inserito (Effettivo)
14 dicembre 2020
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
1 febbraio 2021
Ultimo aggiornamento inviato che soddisfa i criteri QC
27 gennaio 2021
Ultimo verificato
1 gennaio 2021
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EK-VP/25/0/2014
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .